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This study was designed to assess the safety and efficacy of capecitabine and mitomycin C (MMC) in previously untreated patients
with advanced colorectal cancer (CRC). Patients received capecitabine 2500mgm
2day 1, orally divided in two doses of
1250mgm
 2 in the morning and evening for 14 days every 21 days and MMC 7mgm
 2 (maximum total dose 14mg) as an
intravenous bolus every 6 weeks for a total of four courses. The median age was 70 years (range 24–85) and the majority of patients
(86.9%) were of performance status 1/2. The most common metastatic site was liver. In all, 84 patients were assessable for response.
The overall response rate was 38% (95% CI: 27.7–49.3) and a further 33.3% of patients achieved stable disease over 12 weeks.
There was good symptom resolution ranging from 64 to 86%. Grade 3/4 toxicity was as follows: hand–foot syndrome 19.7%;
diarrhoea 10%; neutropenia 2.4%; infection 2.3%. Capecitabine and MMC have shown encouraging activity with a favourable toxicity
profile, a convenient administration schedule, and could be considered for patients deemed unsuitable for oxaliplatin and irinotecan
combinations.
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Colorectal cancer (CRC) is the second most common cancer in
Europe and 500000 patients die from the disease annually
worldwide (Parkin et al, 2001a,b). Although 70–80% of new cases
of colon cancer undergo potentially curative surgery, 40% develop
recurrent or metastatic disease. For many years, fluorouracil (5FU)
has been the backbone of treatment for advanced CRC.
Intravenous bolus injections of 5FU yielded overall response
rates of 10% and a median overall survival (OS) of 11 months.
These results were improved by prolonged infusion of 5FU, which
led to higher response rates, a different toxicity profile and a small
but significant increase in OS to 12 months (Meta-analysis Group
In Cancer, 1998). A variety of modulating agents have been
investigated in combination with 5FU. Leucovorin is the most
widely used agent and has demonstrated an improved 1-year
survival when compared to 5FU alone (48% compared to 43%,
respectively, HR 0.88; 95% CI: 0.81–0.96; P¼0.003) (Piedbois and
Michiels, 2003).
Oxaliplatin and irinotecan are agents that have improved the
outcome in advanced CRC in the last decade. They have been
combined with infused and bolus schedules of 5FU. In two large
randomised studies, irinotecan paired with either bolus 5FU/LV
(IFL) or infused 5FU/LV demonstrated an improved OS compared
to 5FU/LV alone (Douillard et al, 2000; Saltz et al, 2000). A
randomised study of oxaliplatin combined with infused 5FU/LV vs
5FU/LV alone produced superior response rates and progression-
free survival (PFS) for the combination arm. However, the
improvement in OS was not statistically significant (de Gramont
et al, 2000). Recently, a US Intergroup study N9741 demonstrated
an OS benefit with infused 5FU/LV/oxaliplatin (FOLFOX4)
compared to IFL and irinotecan/oxaliplatin (Goldberg et al,
2004). However, 60% of patients receiving FOLFOX 4 crossed
over to irinotecan on disease progression, whereas only 24% in the
IFL arm received second-line oxaliplatin.
Furthermore, there have been concerns over the safety of these
combination regimens, in particular the IFL regimen. Higher than
expected 60-day mortality rates were reported for this regimen in
the above Intergroup N9741 study and the CALGB C89803
adjuvant study due to a gastrointestinal syndrome (diarrhoea,
vomiting, dehydration and neutropenia) and vascular syndrome
(acute fatal myocardial infarction, cerebrovascular accident and
pulmonary embolism) (Rothenberg et al, 2001).
The oral fluoropyrimidines are another class of drug to have
been implemented in the last decade. Capecitabine is an oral
tumour-selective fluoropyrimidine and thus generates 5FU pre-
ferentially at the tumour site. The final conversion step to 5FU is
dependent on thymidine phosphorylase, which is significantly
more active in tumour than normal tissue, hence the specific
targeting of 5FU (Miwa et al, 1998; Schuller et al, 2000).
Capecitabine has been evaluated in two phase III studies in this
setting, employing bolus 5FU/LV as the control arm. Equivalent
times for disease progression and OS were observed in both arms,
and the toxicity profile for capecitabine was notably different with
significantly less diarrhoea, nausea, stomatitis and alopecia than
bolus 5FU/LV (Po0.001) (Twelves, 2002).
In the United Kingdom, the National Institute for Clinical
Excellence (NICE) has issued guidance on the treatment of
advanced CRC based on the currently available data. It has
recommended 5FU/LV in combination with oxaliplatin as first-line
treatment for patients with potentially resectable metastatic disease
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lconfined to the liver. For all other patients, first-line chemotherapy
should be instituted with capecitabine monotherapy or 5FU/LV.
Furthermore, a recent physician-based survey of first-line treat-
ment for advanced CRC revealed that 30% of patients worldwide
still receive fluoropyrimidine monotherapy (Capecitabine Usage
Tracking Study. The Research Partnership, 2004).
Mitomycin C (MMC) has been used in the treatment of CRC for
many years. A randomised study of protracted venous infusion
5FU with or without MMC conducted in this setting resulted in an
improved response rate, failure-free survival (FFS) and better
quality of life, but no OS benefit for the combination arm (Ross
et al, 1997). MMC has also been shown to upregulate intratumour-
al thymidine phosphorylase activity, which may increase syner-
gism with capecitabine (Sawada et al, 1998).
The widespread use of fluoropyrimidine monotherapy in the UK
and the potentially increased synergism of capecitabine with MMC
led to this study design to provide a more efficacious treatment
without compromising tolerability. The aim of the study was to
assess the safety and efficacy of capecitabine in combination with
MMC in previously untreated patients with advanced CRC.
MATERIALS AND METHODS
Eligibility
This open-label nonrandomised phase II study was conducted in
two centres in the United Kingdom and Australia. Written
informed consent was obtained from all patients. The local
research and ethics committee approved the study.
The eligibility criteria were histologically confirmed advanced
colorectal adenocarcinoma, no prior chemotherapy except adju-
vant treatment at least 6 months previously, adequate bone
marrow (platelets4100 10
9l
 1, white count 43 10
9l
 1), renal
(creatinine clearance 430mlmin
 1) and hepatic (o1.5 the
upper limit of normal range) function, WHO performance status
0–2, life expectancy of at least 3 months and no concurrent
uncontrolled medical illness. Patients were excluded if there were
medical or psychiatric conditions precluding informed consent,
renal impairment, known malabsorption syndrome or significant
cardiac disease, arrythmias or angina pectoris.
Therapy
Capecitabine, 2500mgm
2day 1, was given orally divided in two
doses of 1250mgm
 2 in the morning and evening for 14 days,
followed by a 7-day treatment-free interval with each cycle of
treatment being repeated every 21 days. MMC, 7mgm
 2 (max-
imum total dose 14mg), was given as an intravenous bolus every 6
weeks for a total of four courses. Patients continued on treatment
for 12 weeks and were then re-assessed. If there was no disease
progression, treatment continued for a further 12 weeks.
Toxicity evaluation and dose modification
Toxicity was evaluated and graded according to the National
Cancer Institute common toxicity criteria (version 2.0) (Trotti et al,
2000). For grade 3 nonhaematological toxicity, capecitabine
treatment was suspended until resolution and re-initiated with
25% dose reduction for the first appearance and 50% for the
second. For grade 4 nonhaematological toxicity, capecitabine
therapy was either terminated or suspended until resolution, with
a 50% dose reduction on re-initiation at the treating physician’s
discretion. For haematological toxicity, if the absolute neutrophil
count o1.0 10
9l
 1 or the platelet count o100 10
9l
 1,
capecitabine and MMC were delayed until resolution and re-
initiated at full dose for 1 week delay and with a subsequent 25%
dose reduction for 2 week delay.
Safety evaluation
Patients were assessed at baseline with a full medical history and
physical examination including PS, full blood count, serum
biochemistry including electrolytes, hepatic and renal function
tests and serum carcinoembryonic antigen (CEA). During the
study, full blood count, urea and electrolytes, liver function tests
and CEA were performed at weeks 3 and 6 initially, then 6 weekly
thereafter.
Efficacy evaluation
Tumour response by CT assessment was performed according to
RECIST criteria at 12 and 24 weeks (Therasse et al, 2000). FFS and
OS were calculated for all patients from the date of treatment
initiation to the date of disease progression or death, respectively
(intent-to-treat analysis), using the Kaplan–Meier method. Pa-
tients still alive were censored at the date of last contact.
Statistical methods
This phase II study was conducted according to the Simon optimal
two-stage design. The sample size was calculated with 90% power
to detect an objective response rate of 50% and rule out a lower
limit of 25% of this estimate using a one-sided alpha of 0.05. In all,
17 patients were enrolled in the first stage; following this, an
interim analysis was performed. As there were more than five
responding patients, the study proceeded to the second stage and
an additional 20 patients were accrued. After a total of 37 patients,
there were more than 13 responding patients; thus, ethics approval
was sought for a total cohort of 100 patients in order to obtain a
tighter estimate of the response rate (95% CI710%).
RESULTS
A total of 92 patients were recruited between September 2001 and
January 2004. Patient demographics are shown in Table 1. The
median age was 70 (range 24–85) years, the majority of patients
were performance status (PS) 1 and the most common metastatic
disease site was liver.
Chemotherapy delivery
All eligible patients commenced treatment at full dosage for a
planned 24-week course. The median treatment duration was 16
weeks (range 1–24). Dose intensities of the intended starting dose
of capecitabine and MMC were 82 and 78%, respectively.
Treatment delays occurred in 38 (43.7%) patients.
Tumour response and symptomatic response
In all, 84 patients were evaluable for response at the time of
analysis. Eight patients were not evaluable for response: four died
prior to response assessment, one had nonmeasurable disease, one
patient underwent abdominal surgery after one cycle and two
patients have not yet had response assessment at 12 weeks.
Response data are shown in Table 2. There were five complete
responses (CRs) and 27 partial responses (PRs) (overall response
rate 38; 95% CI 27.7–49.3); this represents the best-achieved
response rate.
In total, 28 patients (33.3%) achieved stable disease for a
minimum of 12 weeks and 24 (28.5%) developed progressive
disease. Symptomatic improvement was observed in a large
proportion of patients as shown in Table 3. The bowel symptoms
were in patients with a primary cancer in situ and synchronous
metastases.
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Overall, the treatment was well tolerated and the most commonly
reported events are demonstrated in Table 4. The most significant
grade 3/4 toxicities were hand–foot syndrome (19.7%), diarrhoea
(10%), thrombocytopenia (4.7%) and neutropenia (2.4%). There
were no cases of grade 3/4 stomatitis and grade 2 alopecia did not
occur with this regimen. There were no treatment-related deaths
with this regimen.
Three (3.75%) patients developed red cell fragmentation and
therefore discontinued MMC, but no cases of haemolytic uraemic
syndrome were detected.
Survival
With a median follow-up of 12.7 months, 55.4% of patients had
died at the time of analysis. The median OS for this regimen was
14.3 months (95% CI 11.39–17.2) with 1 year OS of 54.8% (95% CI
41.6–66.1) (Figure 1). The median FFS was 7.11 months (95% CI
6.13–8.10) with 1 year FFS of 26% (95% CI 15.4–38.0) (Figure 2).
Second-line treatment
In all, 29 patients (36.3%) received second-line chemotherapy on
disease progression (10 irinotecan; two irinotecan/gefitinib; six
capecitabine/oxaliplatin; one infused 5FU). Three patients were re-
challenged with capecitabine/MMC and seven with capecitabine
alone; these patients demonstrated a progression-free interval of
X6 months after an initial response to XMMC.
Table 1 Patient demographics
Patient characteristics Number
Total number entered 92
Age median (range) 70 (24–85)
Male/female 55/37
ECOG performance status
0 30 (32.6%)
1 50 (54.3 %)
2 10 (10.9%)
Unknown 2 (2.1%)
Primary site
Rectum 29 (31.5%)
Colon 63 (68.5%)
Original Dukes stage
A1
B1 2
C2 7
D2 9
Unknown 23
Metastatic sites
Liver 62
Lung 34
Nodal 21
Peritoneum 8
Locoregional 11
Histological differentiation
Well 2
Moderate 68
Moderate–poorly 2
Poorly 12
Unknown 8
Table 2 Response to capecitabine/MMC
Best response No of patients (N¼84) % of assessable patients
CR 5 5.95
PR 27 32.1
SD 28 33.33
PD 24 28.57
NE* 8
NE¼nonevaluable; CR¼complete response; PR¼partial response; SD¼stable
disease; PD¼progressive disease.
Table 3 Symptomatic response
Symptom Number %
Pain 18/31 58.1
Anorexia 12/15 80.0
Weight loss 13/15 86.7
Bowel 20/25 80.0
Table 4 Toxicity
Toxicity All grades (N¼86) (%) Grade 3/4 (N¼86) (%)
Diarrhoea 55.8 10.4
Stomatitis 26.7 0
Alopecia 3.7 0
Nausea 40.7 2.3
Infection 10.5 2.3
Hand–foot syndrome 54.7 19.7
Fever 5.8 1.2
(N¼85) (%) (N¼85) (%)
Anaemia 52.9 2.4
Neutropenia 39.3 2.4
Thrombocytopenia 22.4 4.7
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Figure 1 Overall survival (OS): Median OS was 14.3 months (95% CI
11.39–17.2).
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This trial has demonstrated that capecitabine/MMC is an effective
and well-tolerated regimen for patients with untreated advanced
CRC. It produced an overall response rate of 38% (95% CI 27.7–
49.3), median FFS of 7.11 months (95% CI 6.13–8.10) and a
median OS of 14.3 months (95% CI 11.39–17.2). Furthermore,
33.3% of patients achieved stable disease and overall the regimen
produced good symptom resolution. The median OS previously
reported with capecitabine alone was 12.9 months (95% CI 12.0–
14.0) and FFS 4.6 months (95% CI 4.3–5.3) (Twelves, 2002).
Grothey et al recently compared capecitabine with the addition
of oxaliplatin or irinotecan in a randomised phase II study. The
ORRs for capecitabine/irinotecan and capecitabine/oxaliplatin
were 37 and 49.3%, and PFS 8.2 and 6.6 months, respectively
(Grothey et al, 2003). A European phase II study of 43 patients
evaluating capecitabine combined with oxaliplatin demonstrated
an impressive ORR of 55% (95% CI 45–65) and median time to
disease progression (PFS) of 7.4 months; however, there was one
treatment-related death and 11% grade 3/4 sensory neuropathy
(Tabernero et al, 2002). Furthermore, grade 3/4 diarrhoea and
dehydration requiring hospitalisation in another phase II study
evaluating capecitabine and oxaliplatin necessitated a dose
reduction of capecitabine from 2000 to 1500mgm
 2 for 14 days
every 21 days. At the lower dose of capecitabine (1500mgm
 2), the
ORR was 37.1% (95% CI 21.5–55.1) and median PFS was 6.9
months with 20% grade 3/4 diarrhoea and one treatment-related
death (Shields et al, 2004). A phase II study of 56 patients
investigating capecitabine and irinotecan showed an ORR of
45% (95% CI 30–60), and although toxicity was manageable there
were two toxic deaths (Munoz et al, 2003). Therefore, the addition
of capecitabine to MMC may be less efficacious than these
combinations, but is associated with a more acceptable toxicity
profile.
However, the median OS of 14.3 months produced with this
combination is somewhat disappointing, particularly compared to
the 5FU/LV irinotecan and oxaliplatin combinations which have
produced a median OS approaching 20 months (Goldberg et al,
2004). Nevertheless, this may be partly accounted for by a selection
bias in this study – by comparison with other contemporaneous
studies this was an older population (median age 70 years), who
were considered unlikely to tolerate oxaliplatin or irinotecan
combinations. This is also reflected in the use of second-line
treatment which is relatively low – 36.3% compared to 71% in an
audit conducted at our institute of patients who received initial
fluoropyrimidine therapy as part of a tumour vaccine study
(median age 63 years), and 67 and 75%, respectively, in the recent
Intergroup N9471 study for the irinotecan and oxaliplatin arms.
There is relatively little information regarding chemotherapy in
this setting for elderly patients. Our own data have demonstrated
that they derive similar benefits to their younger counterparts
from 5FU-based palliative chemotherapy (Popescu et al, 1999).
Although it has been suggested that irinotecan and oxaliplatin
regimens can be administered to the elderly, they can be associated
with considerable toxicity. A recent retrospective study reported
the tolerance and efficacy of irinotecan or oxaliplatin combination
therapy in 66 elderly patients (age 474 years) with advanced CRC.
In total, 44 and 22 patients received oxaliplatin or irinotecan,
respectively, and the median age was 78 years. Overall, an ORR of
21.5%, median PFS 6.8 months and median OS 11.2 months were
reported in the first-line setting. There was significant toxicity:
42% of patients experienced grade 3/4 toxicity; neutropenia 17%,
diarrhoea 15%, neuropathy 11%, nausea 8% and thrombocytope-
nia 6% (Aparicio et al, 2003). In our study, 30 (32.6%) patients
were X74 years and there were relatively few grade 3/4 toxicities
observed and minimal myelosuppression. Thus, it appears that
capecitabine and MMC can be safely administered to elderly
patients.
Despite the currently available data for chemotherapy in
advanced CRC, there is still considerable variation in practice
among the oncological community worldwide. Indeed, a recent
physician-based survey conducted in several countries (including
North America, Canada and parts of Europe) has demonstrated
that a significant proportion of patients treated with first-line
therapy still receive fluoropyrimidine monotherapy. In the UK,
this figure is particularly high (59%), which may be explained by
NICE guidance. However, the corresponding figures for North
America, Canada and Germany are 30, 32 and 42%, respectively
(Capecitabine Usage Tracking Study. The Research Partnership,
2004). This implies that there is a relatively large subgroup of
patients with advanced CRC, who are deemed unsuitable for
oxaliplatin or irinotecan combination therapy.
In summary, this trial has demonstrated that capecitabine and
MMC is an active and safe combination in untreated advanced
CRC. It provides ease of administration, while avoiding the
potential indwelling venous catheter-related complications, and
can be given in the outpatient setting. It may be a valuable
therapeutic option for those patients considered unsuitable for
irinotecan and oxaliplatin. Furthermore, it offers an alternative
treatment for those patients receiving fluoropyrimidine mono-
therapy, in which context MMC improves efficacy without
incurring additional toxicity.
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